Cannabidiol is a negative allosteric modulator of the cannabinoid CB 1 receptor
British Journal of Pharmacology2015Vol. 172(20), pp. 4790–4805
Citations Over TimeTop 1% of 2015 papers
Abstract
Cannabidiol behaved as a non-competitive negative allosteric modulator of CB1 receptors. Allosteric modulation, in conjunction with effects not mediated by CB1 receptors, may explain the in vivo effects of cannabidiol. Allosteric modulators of CB1 receptors have the potential to treat CNS and peripheral disorders while avoiding the adverse effects associated with orthosteric agonism or antagonism of these receptors.
Related Papers
- → Immunomodulation by cannabinoids is absent in mice deficient for the cannabinoid CB2 receptor(2000)541 cited
- → Synthesis and Characterization of Potent and Selective Agonists of the Neuronal Cannabinoid Receptor (CB1)(1999)372 cited
- → Species comparison and pharmacological characterization of rat and human CB2 cannabinoid receptors(2004)99 cited
- → 6ʺ-Azidohex-2ʺ-yne-cannabidiol: a potential neutral, competitive cannabinoid CB1 receptor antagonist(2004)76 cited
- Design, synthesis and evaluation of fluorescent CB2 cannabinoid receptor ligands(2009)